Japanese multicenter phase II study of CHOP followed by radiotherapy in stage I-II1, diffuse large B-cell lymphoma of the stomach

Satoshi Ishikura, Kensei Tobinai, Atsushi Ohtsu, Shigeo Nakamura, Tadashi Yoshino, Ichiro Oda, Toshiyuki Takagi, Kiyomi Mera, Yoshikazu Kagami, Kuniaki Itoh, Yoshio Tamaki, Junji Suzumiya, Masafumi Taniwaki, Seiichiro Yamamoto

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

CHOP (clophosphamide, doxorubicin, vincristine and prednisone) followed by radiotherapy is regarded as standard care for localized aggressive lymphoma; however, prospective confirmation of its applicability to localized primary gastric lymphoma is inadequate, and most patients in Japan have been initially treated with gastrectomy. We conducted a multicenter phase II study to evaluate the feasibility and efficacy of the non-surgical treatment. Eligibility criteria required primary gastric diffuse large B-cell lymphoma, stage I-II1, age 20-75, performance status 0-1 and adequate organ function. Treatment consisted of three cycles of CHOP followed by radiotherapy 40.5 Gy. Fifty-five patients were enrolled between December 1999 and February 2003, and 52 eligible patients were analyzed. Patient characteristics were as follows: median age, 61 years; 28 men, 24 women; 36 with stage I, 16 with stage II1; 47 with a low International Prognostic Index (IPI) and five with a low-intermediate IPI. All but one patient completed planned treatment. No serious complications including massive hemorrhage or perforation were observed. A complete response was achieved in 48 of the 52 patients (92%, 95% confidence interval: 82-98%) and progressive disease in three. Two patients underwent salvage gastrectomy due to disease persistence or recurrence. With a median follow-up period of 28 months, 2-year progression-free and overall survivals were 88 and 94%, respectively. CHOP followed by radiotherapy is safe and highly effective in localized gastric diffuse large B-cell lymphoma. This organ-preserving treatment should be considered as a very reasonable therapeutic option.

Original languageEnglish
Pages (from-to)349-352
Number of pages4
JournalCancer Science
Volume96
Issue number6
DOIs
Publication statusPublished - Jun 2005

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Stomach
Radiotherapy
Gastrectomy
Therapeutics
Vincristine
Prednisone
Doxorubicin
Disease-Free Survival
Lymphoma
Japan
Confidence Intervals
Hemorrhage
Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Japanese multicenter phase II study of CHOP followed by radiotherapy in stage I-II1, diffuse large B-cell lymphoma of the stomach. / Ishikura, Satoshi; Tobinai, Kensei; Ohtsu, Atsushi; Nakamura, Shigeo; Yoshino, Tadashi; Oda, Ichiro; Takagi, Toshiyuki; Mera, Kiyomi; Kagami, Yoshikazu; Itoh, Kuniaki; Tamaki, Yoshio; Suzumiya, Junji; Taniwaki, Masafumi; Yamamoto, Seiichiro.

In: Cancer Science, Vol. 96, No. 6, 06.2005, p. 349-352.

Research output: Contribution to journalArticle

Ishikura, S, Tobinai, K, Ohtsu, A, Nakamura, S, Yoshino, T, Oda, I, Takagi, T, Mera, K, Kagami, Y, Itoh, K, Tamaki, Y, Suzumiya, J, Taniwaki, M & Yamamoto, S 2005, 'Japanese multicenter phase II study of CHOP followed by radiotherapy in stage I-II1, diffuse large B-cell lymphoma of the stomach', Cancer Science, vol. 96, no. 6, pp. 349-352. https://doi.org/10.1111/j.1349-7006.2005.00051.x
Ishikura, Satoshi ; Tobinai, Kensei ; Ohtsu, Atsushi ; Nakamura, Shigeo ; Yoshino, Tadashi ; Oda, Ichiro ; Takagi, Toshiyuki ; Mera, Kiyomi ; Kagami, Yoshikazu ; Itoh, Kuniaki ; Tamaki, Yoshio ; Suzumiya, Junji ; Taniwaki, Masafumi ; Yamamoto, Seiichiro. / Japanese multicenter phase II study of CHOP followed by radiotherapy in stage I-II1, diffuse large B-cell lymphoma of the stomach. In: Cancer Science. 2005 ; Vol. 96, No. 6. pp. 349-352.
@article{ff79b840a3654441809656e591e71cd2,
title = "Japanese multicenter phase II study of CHOP followed by radiotherapy in stage I-II1, diffuse large B-cell lymphoma of the stomach",
abstract = "CHOP (clophosphamide, doxorubicin, vincristine and prednisone) followed by radiotherapy is regarded as standard care for localized aggressive lymphoma; however, prospective confirmation of its applicability to localized primary gastric lymphoma is inadequate, and most patients in Japan have been initially treated with gastrectomy. We conducted a multicenter phase II study to evaluate the feasibility and efficacy of the non-surgical treatment. Eligibility criteria required primary gastric diffuse large B-cell lymphoma, stage I-II1, age 20-75, performance status 0-1 and adequate organ function. Treatment consisted of three cycles of CHOP followed by radiotherapy 40.5 Gy. Fifty-five patients were enrolled between December 1999 and February 2003, and 52 eligible patients were analyzed. Patient characteristics were as follows: median age, 61 years; 28 men, 24 women; 36 with stage I, 16 with stage II1; 47 with a low International Prognostic Index (IPI) and five with a low-intermediate IPI. All but one patient completed planned treatment. No serious complications including massive hemorrhage or perforation were observed. A complete response was achieved in 48 of the 52 patients (92{\%}, 95{\%} confidence interval: 82-98{\%}) and progressive disease in three. Two patients underwent salvage gastrectomy due to disease persistence or recurrence. With a median follow-up period of 28 months, 2-year progression-free and overall survivals were 88 and 94{\%}, respectively. CHOP followed by radiotherapy is safe and highly effective in localized gastric diffuse large B-cell lymphoma. This organ-preserving treatment should be considered as a very reasonable therapeutic option.",
author = "Satoshi Ishikura and Kensei Tobinai and Atsushi Ohtsu and Shigeo Nakamura and Tadashi Yoshino and Ichiro Oda and Toshiyuki Takagi and Kiyomi Mera and Yoshikazu Kagami and Kuniaki Itoh and Yoshio Tamaki and Junji Suzumiya and Masafumi Taniwaki and Seiichiro Yamamoto",
year = "2005",
month = "6",
doi = "10.1111/j.1349-7006.2005.00051.x",
language = "English",
volume = "96",
pages = "349--352",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Japanese multicenter phase II study of CHOP followed by radiotherapy in stage I-II1, diffuse large B-cell lymphoma of the stomach

AU - Ishikura, Satoshi

AU - Tobinai, Kensei

AU - Ohtsu, Atsushi

AU - Nakamura, Shigeo

AU - Yoshino, Tadashi

AU - Oda, Ichiro

AU - Takagi, Toshiyuki

AU - Mera, Kiyomi

AU - Kagami, Yoshikazu

AU - Itoh, Kuniaki

AU - Tamaki, Yoshio

AU - Suzumiya, Junji

AU - Taniwaki, Masafumi

AU - Yamamoto, Seiichiro

PY - 2005/6

Y1 - 2005/6

N2 - CHOP (clophosphamide, doxorubicin, vincristine and prednisone) followed by radiotherapy is regarded as standard care for localized aggressive lymphoma; however, prospective confirmation of its applicability to localized primary gastric lymphoma is inadequate, and most patients in Japan have been initially treated with gastrectomy. We conducted a multicenter phase II study to evaluate the feasibility and efficacy of the non-surgical treatment. Eligibility criteria required primary gastric diffuse large B-cell lymphoma, stage I-II1, age 20-75, performance status 0-1 and adequate organ function. Treatment consisted of three cycles of CHOP followed by radiotherapy 40.5 Gy. Fifty-five patients were enrolled between December 1999 and February 2003, and 52 eligible patients were analyzed. Patient characteristics were as follows: median age, 61 years; 28 men, 24 women; 36 with stage I, 16 with stage II1; 47 with a low International Prognostic Index (IPI) and five with a low-intermediate IPI. All but one patient completed planned treatment. No serious complications including massive hemorrhage or perforation were observed. A complete response was achieved in 48 of the 52 patients (92%, 95% confidence interval: 82-98%) and progressive disease in three. Two patients underwent salvage gastrectomy due to disease persistence or recurrence. With a median follow-up period of 28 months, 2-year progression-free and overall survivals were 88 and 94%, respectively. CHOP followed by radiotherapy is safe and highly effective in localized gastric diffuse large B-cell lymphoma. This organ-preserving treatment should be considered as a very reasonable therapeutic option.

AB - CHOP (clophosphamide, doxorubicin, vincristine and prednisone) followed by radiotherapy is regarded as standard care for localized aggressive lymphoma; however, prospective confirmation of its applicability to localized primary gastric lymphoma is inadequate, and most patients in Japan have been initially treated with gastrectomy. We conducted a multicenter phase II study to evaluate the feasibility and efficacy of the non-surgical treatment. Eligibility criteria required primary gastric diffuse large B-cell lymphoma, stage I-II1, age 20-75, performance status 0-1 and adequate organ function. Treatment consisted of three cycles of CHOP followed by radiotherapy 40.5 Gy. Fifty-five patients were enrolled between December 1999 and February 2003, and 52 eligible patients were analyzed. Patient characteristics were as follows: median age, 61 years; 28 men, 24 women; 36 with stage I, 16 with stage II1; 47 with a low International Prognostic Index (IPI) and five with a low-intermediate IPI. All but one patient completed planned treatment. No serious complications including massive hemorrhage or perforation were observed. A complete response was achieved in 48 of the 52 patients (92%, 95% confidence interval: 82-98%) and progressive disease in three. Two patients underwent salvage gastrectomy due to disease persistence or recurrence. With a median follow-up period of 28 months, 2-year progression-free and overall survivals were 88 and 94%, respectively. CHOP followed by radiotherapy is safe and highly effective in localized gastric diffuse large B-cell lymphoma. This organ-preserving treatment should be considered as a very reasonable therapeutic option.

UR - http://www.scopus.com/inward/record.url?scp=22444450763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22444450763&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2005.00051.x

DO - 10.1111/j.1349-7006.2005.00051.x

M3 - Article

C2 - 15958057

AN - SCOPUS:22444450763

VL - 96

SP - 349

EP - 352

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 6

ER -